73 related articles for article (PubMed ID: 7787398)
21. Generation of lymphokine-activated killer (LAK) cell activity from malignant peritoneal effusions.
Chao TY; Hwang WS; Yeh MY
Proc Natl Sci Counc Repub China B; 1995 Apr; 19(2):92-8. PubMed ID: 7624448
[TBL] [Abstract][Full Text] [Related]
22. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition.
Mueller EA; Anderer FA
Cancer Res; 1990 Jun; 50(12):3646-51. PubMed ID: 1692765
[TBL] [Abstract][Full Text] [Related]
23. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
Carson WE; Fehniger TA; Caligiuri MA
Eur J Immunol; 1997 Feb; 27(2):354-60. PubMed ID: 9045904
[TBL] [Abstract][Full Text] [Related]
24. Natural killer (NK) and lymphokine activated killer (LAK) cell activity in patients (PTS) treated with flavone acetic acid (FAA).
Galligioni E; Quaia M; Spada A; Crivellari D; Favaro D; Sorio R; Talamini R; D'Incalci M; Allavena P; Damia G
Ann Oncol; 1991 Feb; 2(2):145-50. PubMed ID: 2054317
[TBL] [Abstract][Full Text] [Related]
25. [Soluble interleukin-2 receptor in patients with urinary bladder cancer].
Wen R; Xie S
Zhonghua Zhong Liu Za Zhi; 1996 May; 18(3):224-6. PubMed ID: 9387261
[TBL] [Abstract][Full Text] [Related]
26. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of chemotherapy-induced and HIV-1-induced immunocompromise on NK and LAK activities using breast cancer and HIV-1 seropositive patient populations.
Brenner BG; Gryllis C; Gornitsky M; Cupples W; Wainberg M
Anticancer Res; 1991; 11(2):969-74. PubMed ID: 2064353
[TBL] [Abstract][Full Text] [Related]
28. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
29. Effect of arginase on splenic killer cell activity in patients with gastric cancer.
Wu CW; Chi CW; Ho CK; Chien SL; Liu WY; P'eng FK; Wang SR
Dig Dis Sci; 1994 May; 39(5):1107-12. PubMed ID: 8174424
[TBL] [Abstract][Full Text] [Related]
30. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
31. [Human LAK cell induction and its biological characteristics].
Wu YY
Zhonghua Zhong Liu Za Zhi; 1990 Jul; 12(4):254-7. PubMed ID: 2125554
[TBL] [Abstract][Full Text] [Related]
32. Regulation of CD3- lymphocyte function with an antibody against the IL-2 beta chain receptor: modulation of NK and LAK activity and production of IFN gamma.
Ortaldo JR; Frey J; Takeshita T; Sugamura K
Eur Cytokine Netw; 1990; 1(1):27-34. PubMed ID: 2151685
[TBL] [Abstract][Full Text] [Related]
33. Regulation of natural killer function by nonlymphoid cells.
Shau H; Roth MD; Golub SH
Nat Immun; 1993; 12(4-5):235-49. PubMed ID: 8257829
[TBL] [Abstract][Full Text] [Related]
34. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts.
Dannemann BR; Morris VA; Araujo FG; Remington JS
J Immunol; 1989 Oct; 143(8):2684-91. PubMed ID: 2477453
[TBL] [Abstract][Full Text] [Related]
35. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
Kasid A; Bell GI; Director EP
J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
[TBL] [Abstract][Full Text] [Related]
36. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
37. Elevated concentration of soluble interleukin-2 receptors in serum of smokers and patients with lung cancer. Correlation with clinical activity.
Ginns LC; De Hoyos A; Brown MC; Gaumond BR
Am Rev Respir Dis; 1990 Aug; 142(2):398-402. PubMed ID: 2200317
[TBL] [Abstract][Full Text] [Related]
38. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
39. Natural killer (NK) and lymphokine-activated killer (LAK) cell activity in healthy volunteers with special emphasis on the familial incidence of cancer.
Fujita J; Saijo N; Sasaki Y; Sakurai M; Sano T; Ishihara J; Takahashi H; Hoshi A
Jpn J Clin Oncol; 1985 Dec; 15(4):589-94. PubMed ID: 4094091
[TBL] [Abstract][Full Text] [Related]
40. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
